Search results for "dipyridamole"

showing 10 items of 26 documents

Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.

2003

Abstract Thrombotic thrombocytopenic purpura (TTP) is an uncommon hematologic thrombotic disorder characterized by fever, hemorrhagic and neurologic signs. The advent of plasma exchange has dramatically improved the prognosis of this disease, which was once inevitably fatal. However, mortality rates remain significant. Antiplatelet drugs have been widely used in combination with plasma exchange. In this pilot study we investigated the effects of an adjunctive therapy consisting of the continuous, intravenous infusion of dipyridamole, a modality of administration that has not been previously tested in this setting. Sixteen untreated TTP patients, diagnosed consecutively at our clinic, receiv…

AdultMaleTime FactorsCombination therapyThrombotic thrombocytopenic purpuraPilot ProjectsMethylprednisolonelaw.inventionRandomized controlled trialRefractorylawRecurrencemedicineHumansPlateletIn patientProspective StudiesInfusions IntravenousPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryPlatelet CountMortality rateRemission InductionHematologyDipyridamoleMiddle Agedmedicine.diseaseCombined Modality TherapyDipyridamoleTreatment OutcomeAnesthesiaFemalebusinessPlatelet Aggregation Inhibitorsmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Atherosclerosis and Cerebral Ischemic Attacks: Intakes of Cerebrography With Xenon133 Inhaled and Platelet Tests in the Diagnosis, Clinical and Thera…

1984

A study of patients to develop the significance of the role of the blood plate lets in the recurrence of transient cerebral ischemic attacks in patients with cerebral atheromatous, develop the effectiveness of dipyridamole in the prophy lactic therapeutic regimen. In the group treated with dipyridamole, a 76.3% clinical improvement was recorded (mean increases of 11.2 ml/min. and 11.4 ml/min. of the cerebral hemispheric flows), 15.8% of cases stabilized (mean increases of 1.7 ml/min. and 1.2 ml/min.) and 7.9% failures (mean decreases of 10.4 ml/min. and 14.3 ml/min.) of these same flows. The cerebrography with xenon 133 inhaled as well as the platelet tests used, constitute unfailing means…

AdultMalemedicine.medical_specialtyPlatelet AggregationArteriosclerosismedicine.medical_treatmentVasodilation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPlatelet030212 general & internal medicineAgedAerosolsChemotherapyTherapeutic regimenbusiness.industryDipyridamoleArteriosclerosisMiddle Agedmedicine.diseaseSurgeryTherapeutic monitoringDipyridamoleIschemic Attack TransientCardiovascular agentCardiologyFemaleCardiology and Cardiovascular MedicinebusinessXenon Radioisotopesmedicine.drugAngiology
researchProduct

Usefulness of concomitant myoglobin and troponin elevation as a biochemical marker of mortality in non–ST-segment elevation acute coronary syndromes

2003

Koolen JJ. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 1996;334:1703–1708. 2. Senior R, Kaul S, Soman P, Lahiri A. Power-Doppler contrast echocardiography—a new technique for Assessing myocardial perfusion. Am Heart J 2000; 139:245–251. 3. Picano E, Parodi O, Lattanzi F, Sambuceti G, Andrade MJ, Marzullo P, Giorgetti A, Salvadori P, Marzilli M, Distante A. Assessment of anatomic and physiological severity of single-vessel coronary artery lesions by dipyridamole echocardiography. Comparison with positron emission tomography and quantitative arteriography. Circulation 1994;89:753–761. 4. Jayaweera AR, Wei K, Coggins M, Bin…

AdultMalemedicine.medical_specialtyTime FactorsCoronary DiseaseFractional flow reserveSensitivity and SpecificityHospitals UniversityCoronary artery diseaseElectrocardiographyRisk FactorsCause of DeathInternal medicineSpect imagingHumansMedicineFalse Positive ReactionsHospital MortalityAgedAged 80 and overAnalysis of VariancebiologyMyoglobinbusiness.industryMiddle AgedPrognosismedicine.diseaseTroponinTroponinDipyridamolemedicine.anatomical_structureCoronary stealSpainbiology.proteinCardiologyFemaleTriageCardiology and Cardiovascular MedicinebusinessPerfusionBiomarkersArterymedicine.drugThe American Journal of Cardiology
researchProduct

Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intracoronary stenting

1992

Patients with intracoronary stent implantation are treated with aggressive anticoagulant and antiplatelet therapy consisting of high-dose heparin, phenprocoumon, acetylsalicylic acid, dipyridamole, and the infusion of dextran to prevent a subacute thrombotic occlusion of the stented segment. In an effort to optimize this treatment by reducing both imminent bleeding complications and subacute thrombotic occlusion, the concentrations of prothrombin fragment 1 + 2 (F 1 + 2) were determined after intracoronary Palmaz-Schatz stent implantation in 19 consecutive patients. The F 1 + 2 concentrations after stent implantation and before the initiation of oral anticoagulant therapy (OAT) were 0.35 nm…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentUrologyAdministration OralPhenprocoumonmedicineHumansAngioplasty Balloon CoronaryAgedChemotherapyHeparinbusiness.industryPROTHROMBIN FRAGMENT 1.2AnticoagulantAnticoagulantsHematologyGeneral MedicineHeparinMiddle AgedThrombophlebitismedicine.diseaseThrombosisPeptide FragmentsDipyridamoleHeart Valve ProsthesisAnesthesiaPhenprocoumonFemaleProthrombinStentsPulmonary EmbolismComplicationbusinessmedicine.drugAnnals of Hematology
researchProduct

Glucose and Erythrocyte ATP: Distinctive Effects of Dipyridamole and of Ticlopidine

1987

This experiment suggests the following points: 1. Erythrocytes in control patients and in atherosclerosis patients seem to have a variable grade of affinity for adenosine and for plasma glucose. This variable grade seems to fix the level of the adenosine triphosphate (ATP) reserves and induces the erythrocytes' deformability. 2. The drop in the level of ATP reserves that induces the poor deformability of the erythrocytes in atherosclerosis patients would appear to be caused by two consecutive shortages: first a shortage that seems to be related to a deficiency of erythrocyte adenosine as the ATP shortage disappears with dipyridamole treatment and then a shortage induced by the lack of eryt…

Blood Glucosemedicine.medical_specialtyAdenosineErythrocytesTiclopidineArteriosclerosismedicine.medical_treatmentEconomic shortage030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundAdenosine Triphosphate0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineTiclopidineChemotherapyPlasma glucosebusiness.industryDipyridamoleAdenosineDipyridamoleRed blood cellEndocrinologymedicine.anatomical_structurechemistryDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessAdenosine triphosphatemedicine.drugAngiology
researchProduct

In-vitro and Ex-vivo Inhibition of Blood Platelet Aggregation by Naftazone

1996

Abstract Because of the considerable interest in the role of platelets and antiplatelet therapy in cardiovascular disease, including the aggregation of platelets to each other during arterial thrombosis and atherogenesis, we have studied the effect of naftazone (Etioven), an original vasculotropic drug on platelet aggregation. Rat and human platelets were prepared and incubated in-vitro with different concentrations of naftazone. We found that naftazone inhibited both platelet secretion and aggregation in platelet-rich plasma (PRP) and washed platelets after stimulation with thrombin or ADP. Rats were also treated intraperitoneally for five days with various naftazone doses (0.125-10 mg kg−…

Blood PlateletsMaleSerotoninPlatelet AggregationPharmaceutical ScienceStimulationIn Vitro TechniquesPharmacologyRats Sprague-DawleyThrombinmedicineAnimalsHumansPlateletTiclopidinePharmacologyAspirinChemistryThrombinBiological activityRatsAdenosine DiphosphateDipyridamoleBiochemistryPlatelet Aggregation InhibitorsEx vivoNaphthoquinonesmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Pressure–volume relationship by pharmacological stress cardiovascular magnetic resonance

2021

Abstract Background. The variation between rest and peak stress end-systolic pressure-volume relation (ΔESPVR) is an index of myocardial contractility, easily obtained during routine stress echocardiography and never tested during dipyridamole stress-cardiac magnetic resonance (CMR). We assessed the ΔESPVR index in patients with known/suspected coronary artery disease (CAD) who underwent dipyridamole stress-CMR.Methods. One-hundred consecutive patients (24 females, 63.76±10.17 years) were considered. ESPVR index was evaluated at rest and stress from raw measurement of systolic arterial pressure and end-systolic volume by biplane Simpson’s method. Results. The ΔESPVR index showed a good inte…

Cardiovascular magnetic resonance imagingReproducibilitymedicine.medical_specialtyCardiovascular magnetic resonance imaging; Dipyridamole; End-systolic pressure–volume relation; Myocardial contractilityEjection fractionmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingDipyridamolemedicine.diseaseDipyridamoleContractilityCoronary artery diseaseEnd-systolic pressure–volume relationInternal medicineCardiologyStress EchocardiographyMedicineRadiology Nuclear Medicine and imagingMyocardial contractilityCardiology and Cardiovascular MedicinebusinessCardiac imagingmedicine.drug
researchProduct

Optical studies on the specific interaction of dipyridamole with alpha 1-acid glycoprotein (orosomucoid).

1982

Abstract The interaction of dipyridamole with α1-acid glycoprotein was investigated by circular dichroism and ultraviolet absorbance measurements as well as by equilibrium dialysis experiments. Dipyridamole is bound to the protein via one site of extremely high affinity and by at least one site of considerably lower affinity. Only the association of dipyridamole with the high affinity site produces typical extrinsic Cotton effects. As a result of experimental observations it is concluded that the high affinity site is located in a hydrophobic protein structure of the glycoprotein.

Circular dichroismChemical PhenomenaStereochemistryProtein ConformationPharmaceutical ScienceOrosomucoidIn Vitro TechniquesProtein structuremedicineHumansPharmacologychemistry.chemical_classificationbiologyChemistry PhysicalCircular DichroismTryptophanDipyridamoleOrosomucoidUltraviolet absorbanceDipyridamoleLower affinitychemistryα1 acid glycoproteinbiology.proteinTyrosineSpectrophotometry UltravioletGlycoproteinDialysismedicine.drugProtein BindingThe Journal of pharmacy and pharmacology
researchProduct

Is digital necrosis in COVID-19 caused by neutrophil extracellular traps: Potential therapeutic strategies

2021

Some of the COVID-19 patients present with ischemic lesions of their finger and toes. Standard anticoagulant therapy is usually unsuccessful for the treatment of this unique presentation of COVID-19. In this review current evidence is presented, which supports the hypothesis that these necrotic lesions are primarily related to the formation of neutrophil extracellular traps is blood vessels. Also, currently available and potential pharmaco-logical methods of the management of this unique thrombotic complication are discussed. Drugs that possibly could be used in COVID-19 patients suffering from acute ischemia of distal parts of the extremities particularly comprise DNase I and DNase1L3, whi…

Extracellular TrapsNecrosisNeutrophilsIschemiaPharmacologyExtracellular TrapsNeutrophil extracellular trapsArticleNecrosisDNaseAntithromboticmedicineExtracellularHumansDigital ischemiaSARS-CoV-2business.industryCOVID-19ThrombosisGeneral MedicineHeparinNeutrophil extracellular trapsmedicine.diseaseDipyridamolemedicine.symptombusinessmedicine.drugMedical Hypotheses
researchProduct

Führt hochdosiertes Dipyridamol in der sekundären Schlaganfallprävention zu kardialen Ereignissen?

2001

In einer post-hoc Analyse der European Stroke Prevention Study 2 (ESPS2) wurde untersucht, ob die Gabe von Dipyridamol als Thrombozytenfunktionshemmer bei Patienten mit TIA oder Schlaganfallen das Risiko kardialer Ereignisse erhoht. ESPS2 war eine Sekundarpraventionsstudie an 6602 Patienten nach TIA oder ischamischem Insult, die in vier Armen Acetylsalicylsaure (ASS, 2×25 mg), retardiertes Dipyridamol (DP, 2×200 mg), die Kombination aus ASS plus DP oder Placebo verglich. Es ergaben sich keine Anhaltspunkte dafur, dass DP zu vermehrten kardialen Ereignissen (Angina pectoris, Myokardinfarkt, Tod) fuhrt. Die Kombination aus ASS und DP war allerdings in der Schlaganfallpravention deutlich wirks…

Gynecologymedicine.medical_specialtyChemotherapyHeart diseaseVascular diseasebusiness.industrymedicine.medical_treatmentmedicine.diseaseDipyridamoleCentral nervous system diseaseCombined treatmentmedicineRisk factorCardiology and Cardiovascular MedicinebusinessStrokemedicine.drugZeitschrift f�r Kardiologie
researchProduct